Vistagen announces EPO notice of intention to grant patent to AV-101 for pain

Vistagen announced that the European Patent Office EPO issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain. AV-101 is the Company’s investigational oral prodrug of 7-chloro-kynurenic acid or 7-Cl-KYNA, a potent and selective full antagonist of the glycine coagonist site of the N-methyl-D-aspartate receptor NMDAR . The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.